Oncorx Insights

What Oncorx Insights does

Oncorx Insights is a privately held, early-stage company headquartered in Boulder, Colorado, founded in 2022. The firm describes itself as an AI-driven oncology platform that delivers treatment insights to three distinct customer segments: practicing oncologists, pharmaceutical companies, and health plans. The stated positioning spans the oncology value chain, indicating intent to serve clinical decision support for individual physicians, evidence or market intelligence needs of pharma, and population-level analytics for payers, though it is unclear whether all three are active go-to-market motions or aspirational scope.

The product surface, as described, is an AI-driven platform for oncology treatment insights; however, no specific product modules, technical architecture, proprietary models, data assets, integrations, API endpoints, or third-party benchmarks are disclosed in available sources. The input contains no populated products_and_services, ai_modalities, or proprietary_features fields, and the company's website at the time of capture displayed only a loader/verification placeholder rather than substantive product content. The underlying technology stack, training pipelines, and data sourcing strategy are therefore undocumented.

The business model is similarly opaque. No pricing models, revenue mechanics, contract structures, or customer logos are disclosed, and no funding rounds, M&A activity, partnerships, or management team information were captured. With a headcount of 1-10 employees and no revenue figure available, the company appears to be at a pre-commercial or very early commercial stage. Investors and acquirers should treat the existing data as insufficient to validate product depth, traction, or revenue predictability, and should seek primary-source diligence (product demo, customer references, cap table, and technical documentation) before any investment or transaction decision.

Name

Oncorx Insights

Website

https://oncorxinsights.com

Company type

Private

Founded year

2022

Headcount range

1–10 employees

Short description

Oncorx Insights is a Boulder, Colorado-based, privately held company founded in 2022 that provides an AI-driven oncology platform delivering treatment insights to oncologists, pharmaceutical companies, and health plans. The firm operates at an early stage with 1-10 employees.

Ownership category

akta.pro rank

Product category

Oncology Clinical Decision Support Software

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)

akta.pro secondary industries

Clinical Decision Support & Workflow Integration (EHR/oncology systems) (HLAAANAE), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD)

Keywords

• Oncology decision support
• AI treatment insights
• Precision oncology platform
• Cancer care analytics
• Clinical oncology software

Headquarters

HQ city

Boulder

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales

Core offering

Oncorx Insights operates an AI-driven oncology platform that delivers treatment insights to oncologists, pharmaceutical companies, and health plans. The platform applies artificial intelligence to support clinical and commercial decision-making related to cancer treatment. It is targeted at healthcare providers, life sciences organizations, and payer organizations involved in oncology care.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncorx Insights AI-driven Oncology Platform AI-driven oncology platform that delivers treatment insights to oncologists, pharmaceutical companies, and health plans, applying artificial intelligence to cancer treatment decision support.

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights2 records

Direct peers

• Syapse: Precision-medicine oncology platform that integrates clinical and molecular data to support treatment decisions and real-world evidence for community oncologists, health systems, and life sciences — competes head-on with an oncology CDS platform serving oncologists and pharma.
• Mendel: AI platform that structures clinical and biomedical data for oncology and other specialties to surface treatment insights; emerging pure-play with similar AI/CDS orientation and pharma exposure.
• ConcertAI: Specialized oncology real-world evidence and AI decision-support vendor serving pharma, providers, and payers — directly comparable buyer mix (oncologists, pharma, health plans) and oncology focus.
• Flatiron Health: Roche-owned oncology-specific electronic health record and real-world data platform serving oncologists, academic researchers, and life sciences companies — the canonical direct peer for an AI oncology treatment-insights platform targeting oncologists and pharma.
• Tempus AI: AI-powered precision-medicine platform combining molecular profiling, clinical data, and AI analytics sold to oncologists, health systems, pharma, and payers — overlaps directly in cancer treatment insights, payer/pharma analytics, and AI-native oncology.
• Cota Healthcare: Oncology real-world data and clinical decision support vendor whose COTA NPIQ and pathway products serve oncologists, payers, and pharma — directly overlapping in cancer treatment-insight tooling.

Broad incumbents

• Foundation Medicine (Roche): Roche-owned molecular diagnostics and genomic profiling company whose CGP tests increasingly feed into AI-driven oncology decision support — broad incumbent with oncology biomarkers and pharma/CDS adjacency.
• Veracyte (including HalioDx / Decipher), oncology Dx & CDS: Diversified specialty diagnostics and urologic/oncology decision-support portfolio. Broader incumbent with an oncology treatment-insights surface area, but serves multiple specialty Dx segments rather than pure CDS for oncology.

Emerging players

• Massive Bio: AI-driven oncology clinical-trial matching and treatment-intelligence platform — narrower therapeutic-area overlap (AI oncology for oncology decision-making) but not a direct EHR-integrated CDS competitor.
• Outcomes4Me: AI-powered oncology treatment-insight and clinical-trial app for patients and providers — adjacent, with a more patient-facing lens but overlapping AI-oncology decision-support content.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/oncorx-insights

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncorx Insights